Economic analysis аssortment of medications and the volume of their consumption in Older patients diagnosed with COVID-19 using the example of Antibiotic use
- Authors: Gladunova E.P.1, Shirobokov Y.E.1, Vdoushkina E.S.1, Kareva N.N.2, Borodulina E.A.1
-
Affiliations:
- Samara State Medical University, Ministry of Health Care of Russia
- Saint-Petersburg State Chemical-Pharmaceutical University, Ministry of Health Care of Russia
- Issue: Vol 24, No 7 (2022)
- Pages: 11-16
- Section: Topical theme
- URL: https://journals.eco-vector.com/0025-8342/article/view/114067
- DOI: https://doi.org/10.29296/25879979-2022-07-02
- ID: 114067
Cite item
Abstract
The aim of the study was to analyze the assortment of drugs and the volume of their consumption in patients of older age groups diagnosed with COVID-19.
Materials and Methods. We analyzed 218 case histories of patients with coronavirus infection who were treated in a covid-hospital, successfully treated and subsequently discharged. Groups of hospitalized patients aged over 65 years (study group) and under 65 years (comparison group) were formed. Age, anamnestic, clinical, and laboratory data were studied using standardized databases of patients with COVID-19 (State Registration Certificates No. 2020622119 and No. 2021621990).
The main drugs used to treat patients, the volume of their consumption were studied. Retrospective, logical, graphic, analytical methods of research were used for analysis. Static processing of the obtained data was performed using Statistica 10.0 application software package.
Results and discussion. Antimicrobial drugs, and immunosuppressive drugs to reduce excess immune inflammation were leading in terms of money. Schemes and costs of antibiotic therapy did not differ significantly, in patients older than 65 years imipenem prevailed, in ORIT there was prescription of linezolid, vancomycin and aquapenem.
Conclusions. The course of COVID-19 with lung involvement, hospitalized for inpatient treatment, was approximately similar in elderly and working-age patients, but arterial hypertension and diabetes mellitus predominated among concomitant diseases in elderly patients. The practice of treating new coronavirus infection made its adjustments in improving the provisional guidelines.
Full Text
About the authors
E. P. Gladunova
Samara State Medical University, Ministry of Health Care of Russia
Email: epg87@mail.ru
ORCID iD: 0000-0002-8137-7197
Doctor of Pharmacy
Russian Federation, 89, Chapaevskaya St., Samara, 443099Ya. E. Shirobokov
Samara State Medical University, Ministry of Health Care of Russia
Email: epg87@mail.ru
ORCID iD: 0000-0002-7313-3432
Doctoral student
Russian Federation, 89, Chapaevskaya St., Samara, 443099E. S. Vdoushkina
Samara State Medical University, Ministry of Health Care of Russia
Email: epg87@mail.ru
ORCID iD: 0000-0003-0039-6829
Сandidate of medical sciences, associate professor
Russian Federation, 89, Chapaevskaya St., Samara, 443099N. N. Kareva
Saint-Petersburg State Chemical-Pharmaceutical University, Ministry of Health Care of Russia
Email: epg87@mail.ru
Doctor of pharmaceutical sciences, professor
Russian Federation, 14, Prof. Popov St., Saint-Petersburg, 197022E. A. Borodulina
Samara State Medical University, Ministry of Health Care of Russia
Author for correspondence.
Email: epg87@mail.ru
ORCID iD: 0000-0002-3063-1538
Doctor of Medicine, professor
Russian Federation, 89, Chapaevskaya St., Samara, 443099References
- World Health Organization. Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. URL: http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 (accessed on: 18.11.2021).
- Borodulina EA., SHirobokovYaE., Gladunova EP., Kudlaj DA. Diagnostikaifarmakoterapiya virus-associirovannyhporazhenijlegkih [Virus-associated lung disease]. Klinicheskayafarmakologiyaiterapiya [Clinical pharmacology and therapy] 2020;29(3):61-66.doi: 10.32756/ 0869-5490-2020-3-61-66
- COVID-19 Weekly Epidemiological Update.URL: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---16-november-2021 (accessed on: 18.11.2021)
- Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. doi: 10.1183/13993003.00547-2020
- Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ. 2020;368:m1198. doi: 10.1136/bmj.m1198.
- Raoult D, Zumla A, Locatelli F, Ippolito G, Kroemer G. Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses. Cell Stress. 2020;4(4):66-75. doi: 10.15698/cst2020.04.216
- Yanez ND, Weiss NS, Romand JA, Treggiari MM. COVID-19 mortality risk for older men and women. BMC Public Health. 2020;20(1):1742. doi: 10.1186/s12889-020-09826-8.
- Guillon A, Laurent E, Godillon L, Kimmoun A, Grammatico-Guillon L. Long-term mortality of elderly patients after intensive care unit admission for COVID-19. Intensive Care Med. 2021; 47 (6): 710-712. doi: 10.1007/s00134-021-06399-x.
- Chen Q, Wang L, Yu W, Xi H, Zhang Q, Chen X, Huang K, Lu X, Liu X, Zhang C, Wang J; Chinese Geriatrics Society; National Center of Gerontology. Recommendations for the prevention and treatment of the novel coronavirus pneumonia in the elderly in China. Aging Med (Milton). 2020; 3 (2): 66-73. doi: 10.1002/agm2.12113
- Borodulina E.A., Vasneva Zh.P., Vdoushkina E.S., Borodulin B.E., Povalyaeva L.V. Osobennosti gematologicheskix i gemostaziologicheskix pokazatelej pri koronavirusnoj infekcii Covid-19 i vnebol`nichnoj pnevmonii // Acta Biomedica Scientifica (East Siberian Biomedical Journal). 2021. T. 6. № 1. S. 40-47. doi: 10.29413/ABS.2021-6.1.6
- Shirobokov Ya.E. Gladunova E.P., Borodulina E.A. i dr. Obzor potencial`ny`x preparatov dlya antivirusnoj i uprezhdayushhej protivospalitel`noj terapii novoj koronavirusnoj infekcii, vy`zvannoj virusom SARS-COV-2 // Acta biomedica scientifica. – 2021. – №6 (4). S. 74-86. doi: 10.29413/ABS.2021-6.4.7
- Teymoori-Rad M, Samadizadeh S, Tabarraei A, Moradi A, Shahbaz MB, Tahamtan A. Ten challenging questions about SARS-CoV-2 and COVID-19. Expert Rev Respir Med; 14 (9): 881-888. doi: 10.1080/17476348.2020.1782197.
- Kozlov V.A., Tikhonova E.P., Savchenko A.A. et al. Clinical immunology. Practical manual for infectious disease specialists. Krasnoyarsk: Polikor, 2021. - 563 c.
- Starshinova A.A., Kushnareva E.A., Kudlay D.A. et al. Treatment options for patients with COVID-19: analysis of literature data. Translational Medicine. 2020; 7(3): 30-37.